Canada Markets close in 1 hr 13 mins
  • S&P/TSX

    20,692.76
    +63.84 (+0.31%)
     
  • S&P 500

    4,144.79
    +33.71 (+0.82%)
     
  • DOW

    34,031.17
    +140.15 (+0.41%)
     
  • CAD/USD

    0.7456
    +0.0019 (+0.2550%)
     
  • CRUDE OIL

    77.28
    +3.17 (+4.28%)
     
  • BTC-CAD

    30,962.37
    -80.97 (-0.26%)
     
  • CMC Crypto 200

    531.68
    +5.73 (+1.09%)
     
  • GOLD FUTURES

    1,886.10
    +6.60 (+0.35%)
     
  • RUSSELL 2000

    1,956.50
    -1.22 (-0.06%)
     
  • 10-Yr Bond

    3.6790
    +0.0450 (+1.24%)
     
  • NASDAQ

    12,027.50
    +140.05 (+1.18%)
     
  • VOLATILITY

    18.92
    -0.51 (-2.62%)
     
  • FTSE

    7,864.71
    +28.00 (+0.36%)
     
  • NIKKEI 225

    27,685.47
    -8.18 (-0.03%)
     
  • CAD/EUR

    0.6948
    +0.0017 (+0.25%)
     

Is This Biotech Stock a Buy Following a Landmark Approval?

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.